V. D'Hondt

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

Guillaume Beinse, V. Taly, A. Leary, Aurelia Baures et autres

PURPOSE: ctDNA may offer a noninvasive means to evaluate tumor response and anticipate disease dynamics before radiologic changes in advanced endometrial carcinoma. EXPERIMENTAL DESIGN: This ancillary analysis included patients from the multicenter, randomized, phase II GINECO-UTerin OLAparib (UTOLA) trial (NCT03745950) evaluating olaparib/placebo …

fr, in, lu, br (code pays fourni par la source)

1160P Immune landscape heterogeneity in endometrial carcinoma: Ancillary analyses of GINECO UTOLA trial and CARPEM cohort

Jean‐Philippe Berthet, Amel Kime, F. Joly Lobbedez, Guillaume Bataillon et autres

fr, lu (code pays fourni par la source)

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin et autres

fr, es, at, cz, be, il, de (code pays fourni par la source)